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]Abstract 
 
Taxanes remain first line chemotherapy in management of metastatic breast cancer and 
have a key role in epithelial ovarian cancer, with increasingly common use of weekly 
paclitaxel dosing regimens. However, their clinical utility is limited by the development 
of chemoresistance. To address this, we modelled in vitro paclitaxel-resistance in MCF-
7 cells. We show that at clinically relevant drug doses, emerging paclitaxel resistance is 
associated with profound changes in cell death responses and a switch from apoptosis to 
autophagy as the principal mechanism of drug-induced cytotoxicity. This was 
characterised by a complete absence of caspase-mediated apoptotic cell death (using the 
pan-caspase-inhibitor Z-VAD) in paclitaxel-resistant MCF-7TaxR cells, compared to 
parent MCF-7 or MDA-MB-231 cell lines on paclitaxel challenge, down-regulation of 
caspase-7, caspase-9  and Bim expression. Silencing with SiRNA to BIM. in MCF-7 
parental cells was sufficient to confer paclitaxel resistance, inferring the significance in 
down-regulation of this protein in contributing to the resistant phenotype of the MCF-
7TaxR cell line. Conversely, there was an increased autophagic response in the MCF-
7TaxR cell line with reduced phospho-mTOR and relative resistance to the mTOR 
inhibitors rapamycin and RAD001. In conclusion, we show for the first time that 
paclitaxel resistance is associated with profound changes in cell death response with 
deletion of multiple apoptotic factors balanced by up-regulation of the autophagic 
pathway and collateral sensitivity to platinum. 
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Introduction: 
 
Despite significant improvements in clinical outcomes, metastatic breast cancer (MBC) 
remains an essentially incurable disease.  The major factor limiting long-term control of 
MBC is development of chemotherapy resistance. Significant advances in 
understanding of some mechanisms of anti-cancer drug resistance have not been 
paralleled by introduction of novel strategies to circumvent or avoid resistance in 
clinical practice. A convincing body of experimental evidence implies that defective 
apoptosis may be an important mechanism underlying chemoresistance (1-3).  
 
Here we have examined the evolution of paclitaxel resistance in an MCF-7 cell line -
MCF-7TaxR - grown in the presence of paclitaxel for a limited time period. We have 
previously published data regarding the cross-resistance profile of the MCF-7TaxR line 
(4) which described up-regulation of ABCB1 but little cross-resistance to the natural 
product drugs etoposide, doxorubicin and colchicine. In MCF-7TaxR cells we did not 
see any changes in the expression levels of betaIII tubulin compared with parental 
MCF-7 cells (data not shown), another mechanism cited for paclitaxel resistance (5). 
Initial analyses indicated a marked decrease in the apoptotic response of paclitaxel 
resistant MCF-7 cells to a range of agents. However, attenuation of apoptosis seen in 
MCF-7TaxR cells did not coincide with resistance to many of those agents. Our 
investigation set out to explore the underlying basis for these changes.  Here, we report 
that the reduction of apoptosis occurring upon acquisition of paclitaxel resistance is 
balanced by upregulation of autophagy as the principal mechanism of cytotoxicity and 
cell death.  
 
Materials and Methods 
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Chemicals and reagents 
Reagents were obtained from Sigma Aldrich (Poole, UK) unless stated otherwise. 
Staurosporine (Alexis Biochemicals, Nottingham, UK), RAD001 (Selleck Chemicals 
;Houston, USA), Z-VAD (Bachem, Switzerland), 3-methyl-adenine, LY294002, 
bafilomycin and rapamycin were dissolved in DMSO and stored as stock solutions; 
doxorubicin was made up in sterile distilled water. Paclitaxel (Taxol; obtained from 
Bristol Myers Squibb UK as a pharmacy preparation) and cisplatin were diluted in 
sterile 0.9% saline as stock solutions stored at -20 °C until use.  
 
Cell Culture: 
The human breast cancer cell line MDA-MB-231 (ATCC from LGC Promochem, 
Teddington, UK) was cultured in L15-Leibovitz medium (Sigma Aldrich, Poole, UK). 
The human breast carcinoma MCF-7 cell line was obtained from the European 
Collection of Cell Cultures (ECACC; Porton Down, Salisbury, UK) and maintained at a 
low passage number throughout the study. Cell lines were authenticated at source by 
STR profiling, morphology (ATCC) and DNA profiling (ECACC).  MCF-7 sublines 
were cultured in Dulbecco’s Modified Eagles (Sigma Aldrich; Poole, UK) modified 
media with 2mM of Glutamax® and supplemented with 10% heat-inactivated foetal 
bovine serum (FBS; Invitrogen, Paisley, UK) at 5% CO2/ 37ºC.  Cell lines with 
acquired resistance to paclitaxel were generated by growth in incrementally increasing 
concentrations with successive passages, (Figure 1). The resulting MCF-7 cell line with 
paclitaxel resistance, designated MCF-7TaxR, was maintained at 6 nM paclitaxel with 
treatment at alternate passages. The established MCF-7TaxR cell line was designated as 
those cultures with passage number exceeding 23. Withdrawal of paclitaxel from the 
culture medium in MCF-7TaxR cells at passage 40 with subsequent culture as for 
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parental cells over several weeks (> 9months) resulted in the cell variant MCF-7TaxR(-
). This subline was developed to examine the stability of the drug resistant phenotype.  
All cell lines were grown in drug free media for at least one passage before 
experimental use. Mycoplasma testing was carried out regularly using a PCR based 
methodology. 
 
Cytotoxicity testing: 
Human breast cancer cells MCF-7, MCF-7TaxR passage 8, MCF-7TaxR passage 18 
and MCF-7TaxR passage 23 were grown in 96-well plates at a density of 3x104/ml  for 
24h. Drugs were diluted in supplemented tissue culture medium and added in increasing 
concentration, with untreated wells as controls. Cells were then incubated for a period 
of 96h and subjected to the MTT assay. This incubation period accounted for the 
doubling times of the cell lines (which did not vary significantly between parental and 
resistant variants) and allowed for an approximate 10-20-fold increase in cell number of 
control cells during this time period. For treatment with rapamycin and RAD001 cells 
were subjected to staining with trypan blue and cell counting used as a measure of cell 
viability. This method was also used to confirm the MTT data previously obtained that 
indicated paclitaxel resistance for MCF-7TaxR cells, set up alongside parental MCF-7 
cells for comparison.  IC50 values (calculated as the dose necessary to cause a 50% 
reduction in cell viability relative to untreated control cells) were calculated from dose 
response curves using PRISM software.  
 
AnnexinV with PI methodology for apoptosis with flow cytometry 
Cells were seeded into tissue culture flasks to give approximately 50% confluence, 
allowed to attach for 2-3 hours and then treated for a period of 24-48h with the 
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appropriate compound at various concentrations (see figure legends). Cells for treatment 
with the pan-caspase inhibitor Z-VAD (100µM ) were allowed to settle and then treated 
for 1h prior to treatment with staurosporine (1μM) for 24h  or with paclitaxel (20nM) or 
cisplatin (20μM) for a period of 48h. An Annexin V-FITC conjugated apoptosis detection 
kit incorporating PI was used as described by the manufacturer’s protocol (Oncogene; 
supplied by CN Biosciences, Beeston, UK).  Harvesting of cells included collection of 
attached cells following trypsinization and floating cells which were combined in the 
sample for processing. Analysis by flow cytometry used the FL1 (FITC) and FL3 (PI) 
laser lines and each sample was assessed using a collection of 10,000 events. 
 
Western blotting analysis 
Whole cell lysates were made from monolayers of cultured cell in the exponential phase 
of growth.  Cells were subjected to various treatment protocols (as indicated in Figure 
legends) after seeding into tissue culture flasks at 30-40% confluence and left to 
equilibrate for 24h.  Cells were harvested by scraping or by use of a non-enzymatic cell 
dissociation fluid, washed twice in PBS and then resuspended in hypotonic lysis buffer 
containing detergent and protease inhibitors. 50 µg of membrane protein was loaded 
onto SDS-PAGE gels and electrophoresed (Novex system, Invitrogen), and western 
transferred to a PVDF membrane. Probing of the membranes for beta actin or GAPDH 
levels to act as loading controls was carried out by membrane stripping with 1mM of 
sodium azide in PBS for 1 h followed by incubation using murine antibody to actin or 
GAPDH (Sigma Aldrich, UK).Visualisation was carried out using anti-rabbit or anti-
mouse alkaline phosphatase conjugated secondary antibody (WesternBreeze) with 
chemiluminescent substrate (CDP Star) both obtained from Invitrogen™. 
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Qualitative PCR analysis 
RNA was extracted from monolayers of human breast cancer cell lines using Trizol 
reagent (Invitrogen™) according to the manufacturer’s instructions. qPCR analysis was 
carried out using SYBRgreen reagent (One-step QuantiTect® Qiagen, Crawley, UK). 
Primers for caspases 7 and 9 were from SuperArray® (obtained from Tebu-Bio, 
Leicester, UK) . The PCR reactions were carried out using the TaqMan® 700 ABI 
Prism with software from Applied Biosystems, setting the cycles as follows: 
30min/50°C for reverse transcription; 15min/95°C PCR initial activation step; 40 cycles 
of denaturation for 20 sec/95°C and annealing step for 60 sec/60°C. Fold changes were 
calculated using the formula 2-(ΔΔCt), where ΔΔCt is the ΔCt (Snk)-ΔCt (GAPDH) and Ct is 
the cycle at which the threshold is crossed. 
 
Transfection with BIM SiRNA :   
MCF-7 cells were subjected to transfection with siRNA to BIM (Dharmacon; 
distributed by ThermoScientific/AbGene Ltd, Epsom UK) reagent SiGENOME 
(product code D-004383-20), target sequence : GUUCUGAGUGUGACCGAGA, using 
transfection reagent DharmaFECT1 (product code T-2001-02) according to 
manufacturer’s instructions with OPTIMEM medium (Invitrogen, Paisley, UK). The 
appropriate negative controls were used according to the manufacturer’s protocols. 
 
Acridine orange staining for detection of acidic vesicles: 
In order to detect and quantify the acidic vesicle formation during the process of 
autophagy MCF-7 cell lines were exposed to 1μM staurosporine treatment for 24h. 
Cells were then harvested by trypsinisation. Cells were washed twice with PBS and then 
stained with acridine orange solution (Sigma Aldrich) at a final concentration of 2ng/ml 
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for 30 minutes in the dark. Acridine orange is a weak base that can accumulate in acidic 
spaces and emits bright red fluorescence (measured at FL4). The intensity of the red 
fluorescence is proportional to the degree of acidity and /or volume of the cellular acidic 
compartments. Bafilomycin treatment is used to inhibit the autophagosome formation. 
The extent of autophagy (as a % on the FL4 scale) is thus assessed as the extent of red 
fluorescence minus that seen in the presence of bafilomycin. 
 
Fluorescence Confocal Microscopy for detection of LC3:  
Cells were seeded into T25cm2 tissue culture flasks at densities of 2 x105 (MDA-MB-
231) or 3 x105 (MCF-7, MCF-7TaxR) and left for 24h under standard culture 
conditions. Cells were then treated with a sub-cytotoxic dose of staurosporine at a dose 
of 0.25μM or 0.5 μM for a further 24h. Cells were harvested using standard 
trypsinization with collection of the floating cell population and processed using the 
Cytospin 4 cytological centrifuge (ThermoElectron Corporation, Basingstoke, UK). The 
cytospin slides were then fixed in 2-4% paraformaldehyde/PBS for 15minutes and 
rinsed in PBS. Slides were then covered in ice-cold methanol and kept at -20o C for 10 
minutes (permeabilization stage). Following PBS rinsing slides were blocked with 5% 
goat serum for non-specific binding for 1 h. This was then followed by overnight 
incubation with primary antibody (LC-3B; Cell Signaling Technology) at a dilution of 
1:200 in PBS-Triton, in an humidifying chamber at 4o C. Slides were then washed with 
PBS and incubated with the secondary antibody conjugated to Alexa-Fluor488 anti-
rabbit secondary antibody (Molecular Probes, Invitrogen), for 2h. After rinsing with 
PBS then the nuclear dye TOPRO3 (Nuclear Probes, Invitrogen) was applied for 
10mins with a final washing using high-salt PBS. Slides were left to air-dry and then 
Anti-Fade reagent for mounting used on a coverslip. The edges of the slides were then 
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sealed with standard commercially available nail lacquer. Images were produced by 
confocal microscopy using a Carl Zeiss Laser Scanning System, LSM510 at x 40 
magnification. 
 
Results 
Paclitaxel-resistant MCF-7 cells show an unusual spectrum of cross-resistance in the 
presence of P-glycoprotein: 
We tested whether an MDR phenotype was present by challenging the cells with 
doxorubicin and an irrelevant cytotoxic drug cisplatin, Figure 1B. During the 
development of paclitaxel resistance, MCF-7 cells showed a gradual upregulation of the 
MDR transporter P-glycoprotein (first evident at passage #23 when paclitaxel resistance 
was established (Figure 1B and Figure 2A).  At this point in spite of up-regulation of 
MDR1, a multidrug resistant profile was not evident in the MCF-7TaxR cells from 
passage 23 onwards as only a modest increase in doxorubicin resistance was apparent 
and resistance to other MDR associated agents, including etoposide was not seen (4). 
Interestingly, we saw a collateral sensitivity to cisplatin (Figure 1B) and to carboplatin 
(data not shown). 
 
Loss of caspase-7 and -9 is associated with emerging paclitaxel resistance 
As part of the characterisation of the resistant cell line MCF-7TaxR we examined the 
role of apoptotic cell death response.  As part of this analysis we assessed expression of 
caspase-7 and -9 in MCF-7 cells with increasing resistance to paclitaxel. Down-
regulation of protein expression was first evident at passage 18 when cells were 
establishing resistance at a dose of 6nM paclitaxel and the mRNA levels of both genes 
was undetectable from passage 23 onwards (Figure 2A and Figure 2B). Loss of 
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expression of caspases -7 and -9 was a stable molecular event as the MCF-7TaxR(-) 
variant line failed to show re-expression of either gene following several months of 
culture in the absence of paclitaxel.  
 
Development of a paclitaxel resistant MCF-7 cell line gives rise to marked changes in 
pro-and anti-apoptotic factors 
Next we analysed MCF-7TaxR cells for expression of pro-and anti-apoptotic proteins. 
There was a striking reduction in expression of BIM and BCl2 between passages 18-23, 
but levels of BAD were stable (Figure 2A). 
 
Absence of BIM as a factor contributing to paclitaxel resistance: 
To evaluate a potential role for loss of BIM underlying the development of paclitaxel 
resistance, we used SiRNA to selectively block BIM expression in MCF-7 parental 
cells. SiRNA produced efficient down-regulation of BIM and on subsequent challenge 
with paclitaxel a reduced apoptotic response was seen (Figure 2C). A series of repeat 
experiments showed that at 48h viability in control (non-silenced) cells following 
paclitaxel treatment (20nM) was 65.3% (relative to the viable population of the 
respective control). The corresponding data for the BIM silenced population was 85.8%. 
As indicated in the figure legend, these data were shown to be statistically different 
from each other. Data indicate that if taken as a factor in isolation, deletion of BIM is 
sufficient to confer resistance to paclitaxel in MCF-7 cells.  
 
Paclitaxel-resistant MCF-7 cells show loss of caspase-mediated cell death: 
We tested for the ability of apoptotic induction in paclitaxel resistant MCF-7TaxR by 
challenging cells with staurosporine (an agent frequently used to demonstrate 
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apoptosis), paclitaxel and cisplatin in the absence or presence of the pan-caspase 
inhibitor Z-VAD using the annexinV assay with flow cytometric analysis. Figure 3A, 
indicates the extent of protection afforded by Z-VAD pre-treatment of cells to a dose of 
staurosporine. Small panels C indicate the induction of cell death (FITC and PI positive 
populations) and the protective effect afforded by Z-VAD,  small panels D. Figure 3B 
indicates the extent of Z-VAD protection from caspase-mediated staurosporine induced 
cell death in 3 breast cancer cell lines (n=4) based on the size of the viable cell 
population (lower left hand quadrant of panels C and D). Overall, the involvement of 
caspase-mediated cell death following staurosporine treatment was of the order MDA-
MB-231> MCF-7 > MCF-7TaxR. MDA-MB231 cells were chosen as a caspase-
proficient line (7). Figure 3C shows the effects of cisplatin and paclitaxel following 48h 
of continuous exposure. Treatment of cells with Z-VAD beyond 48h is toxic and 
therefore we could only use this treatment schedule. Moreover, treatment of MCF-
7TaxR cells with a high dose of paclitaxel plus Z-VAD proved much more toxic than 
the same dose of paclitaxel alone. Hence, our data show the effects of 20nM paclitaxel, 
producing a loss of viability of approximately 25% in MCF-7 and only 8% loss of 
viability in the paclitaxel –resistant MCF-7TaxR line. Treatment of cells with cisplatin 
for 48h show more loss of viability for MCF-7 than for MCF-7TaxR. This is in contrast 
to the MTT data that show relative sensitivity of the MCF-7TaxR cells to the effects of 
platinum. It is important to note that a marked growth inhibitory effect is seen with 
cisplatin and this will be measured by a lack of MTT reduction in the chemosensitivity 
testing– and this was effect was pronounced in the MCF-7TaxR line. 
 
Paclitaxel resistance is associated with diminished apoptotic response but upregulated 
autophagy 
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Treatment of MCF-7 and MCF-7TaxR cells with staurosporine with and without 
bafilomycin (an inhibitor of autophagic vesicle formation) then subjected to flow 
cytometric analysis with acridine orange, indicated an enhancement of acidic vesicle 
formation for the paclitaxel resistant variant, which was shown to be statistically 
significantly different for MCF-7TaxR, based on t-test results (Figure 4A). Thus, 
treatment of MCF-7 and MCF-7TaxR lines with staurosporine resulted in a marked 
stimulation of autophagy for the latter. Inhibition of mTOR was noted for both MCF 
cell lines examined, but more apparent for MCF-7TaxR cells, as seen in the 
disappearance of phosphorylated AKT, phophorylated mTOR and also the downstream 
substrate p60S6 kinase (p60S6-K), Figure 4B.  
Figure 5 shows immunofluorescence for LC-3II using confocal microscopy, indicating 
the extent of autophagy present in staurosporine treated breast cancer cell lines. For the 
caspase-proficient MDA-MB-231 cell line evidence of LC3II expression was not seen, 
Figure 5A panel iv, whereas for MCF-7 presence of the LC-3II form in cells treated 
with 1µM staurosporine was seen, indicated by the heavy (green) staining,  Figure 6B 
panel iv. Figure 5C shows the extent of LC3II formation for the established MCF-
7TaxR line, panel iv, which is the heaviest staining seen for the three cell lines showing 
clear autophagosome vesicular formation, shown more clearly in Figure 5D. 
 
Collateral cisplatin sensitivity is associated with mTOR inhibition 
Using the autophagy inhibitors 3-methyl adenine and LY294002 we could see 
significant inhibition of cisplatin cytotoxicity, giving rise to increased IC50 values, as 
assessed using the MTT assay, Figure 6A. Whilst the effects of these two inhibitors 
were shown to be statistically significant in MCF-7 parental cells, the effects were more 
pronounced for the MCF-7TaxR cell line when treated with LY294002. These data 
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provide evidence that the major cell death response found in MCF-7TaxR cells is 
autophagy. 
 
Upregulation of the autophagic pathway gives rise to rapamycin resistance: 
MCF-7 and MCF-7TaxR cells were subjected to chemosensitivity testing with 
rapamycin and the IC50 values were shown to be 29.4µM (-/+7.4) and 64.6 µM (-/+ 9.6)  
respectively, Figure 6B. Using the mTOR inhibitor RAD001 (IC50 95.5nM-MCF-7; 
150nM- MCF-7TaxR) we could see a gradual reduction in the LC3II form following 
treatment with RAD001 (100nM) in MCF-7TaxR cells with increasing passage number, 
with the established resistant line showing MCF-7TaxR showing negligible amounts of 
LC3II formation, Figure 6C. The survivin expression levels were markedly reduced in 
the MCF-7 parental cell line following treatment with RAD001 whereas for the MCF-
7TaxR variant sublines the expression levels of this IAP were consistently expressed 
with no variation following drug treatment. These data also indicate that as the survivin 
level in MCF-7 cells were markedly reduced with rapamycin treatment there is a 
possibility for some apoptotic induction, but this effect was not seen for the subvariants 
of the MCF paclitaxel resistant lines. These particular data are consistent with activation 
of caspases for the MCF-7 parental line giving rise to activation of the mitochondrial 
pathway, whereas for the caspase-9 deficient MCF-7TaxR passage 18 and 23 variants 
and the established MCF-7TaxR line such an effect was not seen. 
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Discussion 
We have derived paclitaxel-resistant MCF-7 human breast cancer cells using a drug 
exposure protocol similar to clinically used weekly paclitaxel regimens (3weeks 
treatment followed by one week off for 4 cycles; 8) and employing drug doses well 
within the safety margins for clinical acceptable circulating levels of paclitaxel i.e. 
<50nM. We have used parental and paclitaxel resistant cell lines to investigate changes 
in gene expression and cell death pathways which accompany paclitaxel resistance. Our 
data show that there are significant changes in expression of key regulators of cell death 
pathways and a striking switch from apoptosis to autophagy with increasing paclitaxel 
resistance. 
 
A major finding in the present study was loss of expression of caspases 7 and 9 in MCF-
7TaxR cells. Since the first description of caspase-3 deficiency in MCF-7 cells with a 
47bp deletion in exon 3 of the CASP-3 gene (9) an association of caspase-deficiency 
with chemoresistance has been made.  Interestingly, many breast cancer cell lines show 
weak expression of caspase-3 (7). Furthermore, it was reported that 75% of primary 
breast carcinomas have downregulation of caspase-3 mRNA, as seen in samples taken 
from breast cancer patients (10).  Interestingly, peritumoral tissue also showed low 
expression of caspase-3 which suggests that loss of this caspase may be an important 
mechanism of survival for breast cancer cells. Those initial findings have been 
independently supported in studies reporting an association of caspase-3 deficiency with 
poor outcome in breast cancer (11).  In the present study, we show deletion of caspases 
associated with the mitochondrial intrinsic pathway as a consequence of paclitaxel 
resistance in human breast cancer cells. We are not aware of previous reports citing loss 
of caspases 7 and 9 in association with taxane resistance. We are confident that the 
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effects we are seeing are not relating any major mitochondrial dysfunction. As far as we 
can see the function of the mitochondria in the MCF-7TaxR is not impaired as we saw 
efficient reduction of MTT in the cytotoxicity tests used through out this study and 
these data were corroborated by assessment of viability using trypan blue (not shown). 
In other studies we carried out we saw that caspase-8 expression and reactivity to anti-
FAS was almost identical for the parental and paclitaxel resistant MCF-7 cell lines 
alike, (data not shown). This led us to believe that the modulation of apoptosis we saw 
in the MCF-7TaxR line was predominantly relating to the intrinsic pathway. 
 
A second important observation was loss of BIM expression in MCF-7TaxR. BIM – the 
B-cell lymphoma 2 Interacting Mediator of cell death is a potent pro-apoptotic member 
of the Bcl2 family (12), essential for induction of cell death and to mediate cytochrome 
c release from mitochondria which in turn activates apoptosome formation and the 
effector caspase-9. Here we show using inhibitory RNA that BIM knock-down in parent 
MCF7 cells phenocopies MCF-7TaxR, implicating BIM as a key determinant of 
sensitivity to paclitaxel. Consistent with the present results in MCF-7 cells, knock-down 
of BIM reduced paclitaxel cytotoxicity in neuroblastoma cells but failed to protect 
against etoposide or cisplatin induced death (13). In partial agreement with this, in our 
drug resistant cell line MCF-7TaxR loss of BIM expression was accompanied by a 
collateral increase in sensitivity to cisplatin. Interestingly, we earlier showed that 
sensitivity of P-glycoprotein expressing MCF-7TaxR cells to etoposide was unchanged 
compared to the parental cell line (4). Previously, upregulation of P-glycoprotein has 
been reported to result in resistance to etoposide (14). As such, our data obtained for 
MCF-7TaxR are somewhat unusual and imply that upregulation of P-glycoprotein per 
se is insufficient to mediate etoposide resistance. It is also interesting to note that at the 
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point when resistance to paclitaxel became more marked in the developing MCF-7TaxR 
cells, this coincided with the disappearance of BIM (passage #18).  
 
Perhaps the most striking observation from our studies is the switch from apoptosis to 
autophagy as the major mechanism of cell death in MCF-7TaxR cells. A study which 
looked at the autophagic response of ovarian cancer cells treated with RAD001 reported 
that cisplatin resistant cell lines were significantly more sensitive, supports our findings 
(15). Cisplatin-sensitive MCF-7TaxR cells were markedly more resistant to rapamycin, 
in line with a reciprocal relationship for the sensitivity of cancer cells to these two 
agents. The emergence of increasing sensitivity to platinum agents is of particular 
interest and is relevant to the management of breast and ovarian cancers. The data 
describing sensitivity of MCF-7 cells to RAD001 are in close agreement with a report 
by Treck et al. (16) and other data we show indicates that when autophagy survival fails 
in the MCF-7TaxR line then death occurs predominantly via autophagy. A study which 
looked at the autophagic response of cisplatin –sensitive and –resistant clear cell ovarian 
cancer cells when treated with RAD001 is in some agreement with our current study 
(Mabuchi et al. 2010) which reported that cisplatin resistant cell lines were shown to be 
significantly more sensitive to RAD001. In the current study, cisplatin-sensitive MCF-
7TaxR cells were shown to be significantly more resistant to rapamycin, suggesting a 
reciprocal relationship for the sensitivity of cancer cells to these two agents.  
 
 
AKT has previously been described as an important determinant of chemosensitivity for 
many kinds of cells (15). Currently we have shown that there was little evidence of 
phospho -mTOR expression and no evidence for activation of AKT when MCF-7TaxR 
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cells were treated with staurosporine, in line with an enhanced autophagic response, 
with modest but nevertheless higher expression levels of these proteins seen for parental 
MCF-7 cells.  A report by Faried et al. (17) described significant reductions in AKT 
induced following paclitaxel treatment but increases in phosphorylated mTOR in 
cervical cancer cells. Further, the same report described a lack of correlation between 
AKT levels and paclitaxel sensitivity but a closer correlation was seen with mTOR 
levels. RAD001 can effectively inhibit mTOR signalling and this resulted in a marked 
reduction in phosphorylated p70S6K with little effect on phospho-AKT expression in 
ovarian cancer cells (15). In agreement with this we showed that staurosporine treated 
MCF-7TaxR cells markedly attenuated levels of the mTOR substrate phospho-p70S6K. 
Confirmation of the marked autophagic response elicited in staurosporine treated MCF-
7TaxR cells was seen in confocal images where marked LC3II formation was seen in 
MCF-7TaxR cells. In contrast, rapamycin resistant MCF-7TaxR variant cell lines failed 
to undergo autophagic cell death following treatment with RAD001. When the various  
paclitaxel-resistant sublines of MCF-7 were subjected to treatment with RAD001, we 
saw no evidence of formation of LC-3II, in line with the relative resistance of these cells 
to the drug, compared with the parental line. The disappearance of survivin in MCF-7 
treated cells is in some agreement with Kang et al. (18) who described a cross-talk 
between autophagy and apoptosis, wherein degradation of survivin is seen via a beclin 
mediated pathway. As both pathways are operative for MCF-7 cells this effect was seen, 
but where there was an absence of functioning apoptosis then survivin levels remained 
constant. 
 
In order to explain the effects we have seen in the developing paclitaxel resistance of 
MCF-7 cells there are a number of factors we can consider. A polyploidy state has been 
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described in resistance to paclitaxel (19) and indeed there are many genes that are 
implicated in taxane resistance that have roles in the maintenance of chromosomal 
stability (20; 21). Thus, paclitaxel is deemed to be more effective in cell populations 
that are chromosomally stable, whereas therapies such as trastuzumab have activity in 
more unstable cell populations (22). An aneuploid state with a high number of DNA 
breakpoints has been associated with preferential sensitivity to platinum agents in 
breast, ovarian and gastric cancers (22). 
 
Finally, our data highlight the very important observation that the absence of an 
apoptotic response results in abolition of an MDR phenotype in the presence of P-
glycoprotein upregulation. A report by Johnstone et al. (23) described the protection of 
leukaemic cells by the presence of upregulated P-glycoprotein against caspase-
dependent but not caspase-independent cell death. This report corroborates our finding 
that caspase-deficient or caspase-inactivated, P-glycoprotein expressing paclitaxel-
resistant breast cancer cells do not show cross-resistance with doxorubicin, colchicine or 
etoposide as shown by the present study and previous work by us (4). We did see, 
however, that the MDR-reversing agent Tariquidar (XR9576) was able to reverse 
paclitaxel resistance in the MCF-7TaxR line, whereas the sensitivity to the other MDR-
associated agents was unchanged. The basis for this agent-specific effect is currently 
unclear and highlights the complexity of the MDR phenotype. 
 
In conclusion, we have shown that development of resistance to the commonly used 
chemotherapeutic agent paclitaxel gives rise to significant molecular changes which 
culiminate in a caspase-deficient genotype dictating a predominantly autophagic 
response to chemotherapeutic agents. Our data also suggest that in the absence of 
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multiple caspases and also of several BCL2 family members marked attenuation of 
MDR takes place. These findings have implications for breast cancer treatment where 
low expression levels of caspases may be prevalent. 
 
 
 
 
 
 
 
 
 
 
TITLES AND LEGENDS TO FIGURES 
 
FIGURE 1: 
A: Schema for development of paclitaxel resistant cells in culture starting with parental  
MCF-7 cells at passage 1, week 1. RF indicates resistance factor, RF (i.e. IC50 for 
resistant variant : IC50 for parental cells. * indicates a drug free passage to enable cells 
to recover from drug treatment. 
B: Sensitivity to paclitaxel, doxorubicin and cisplatin in MCF7 cells with emerging 
resistance to paclitaxel. MCF-7TaxR cells with increasing resistance to paclitaxel were 
challenged with the indicated drugs and cytotoxicity determined using the MTT assay. 
Data shown are the mean IC50and SD (shown by error bars) of at least 4 repeat analyses. 
 
FIGURE 2: 
A Western-immunoblotting of variant sublines of developing MCF-7TaxR lines. Whole 
cell lysates were loaded onto SDS-PAGE gels (NOVEX, Invitrogen) at a concentration 
of 50ug and electrophoresis using Tris-Bis gels 10-12% followed by transfer onto 
PVDF membranes. Primary antibodies to P-glycoprotein (P-gp), Bax, BCl2 were 
obtained from Santa Cruz, those for caspase-7 and 9, Bad and phosphorylated Bad and 
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Bim were from Cell Signaling Technologies ( distributed by New England Biolabs, 
Hitchin, UK) and then subjected to incubation with a secondary-alkaline phosphatase 
conjugated antibody with subsequent chemiluminescent detection. All membranes were 
stripped and reprobed with an antibody to beta actin (Sigma Aldrich), n= 3. 
 
B : Quantitative PCR for assessment of mRNA levels of -7 and -9 on sublines of 
developing paclitaxel resistant MCF-7 cells. Data shown are corrected for GAPDH 
expression using the equation 2-Ct . 
C  Transfection of MCF-7 cells with SiRNA against BIM (Dharmacon) followed by 
drug treatment (20nM paclitaxel for 48h)  subjected to flow cytometry using the 
annexin V assay with PI. The percentage of live cells (expressed as a percentage of the 
untreated control) is indicated in the bottom left hand corner (PI and FITC negative 
cells) of the quadrant cytogram and data shown are representative of repeat data (n = 3). 
Comparisons of live populations of non-silenced cells versus BIM-silenced cells gave a 
p value of 0.03 using a paired t-test.    
Assessment of efficiency of knock-down of BIM was made by western analysis (as 
described in Methods).  
 
FIGURE 3: 
A: Cytograms obtained from AnnexinV assays of staurosporine (1µM) treated breast 
cancer cells. Each cytogram consists of data showing live cells (PI and FITC negative) 
bottom right; early apoptotic population (FITC positive) bottom right; mid-late stage 
apoptosis (PI and FITC positive) top right; necrotic/end stage apoptotic cells (PI 
positive, FITC negative) top left. A = control untreated cells; B = Z-VAD treated 
control cells; C= staurosporine treated cells; D = staurosporine and Z-VAD combination 
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treatment. The live cell population is indicated for each sample and is representative of 
typical data obtained. 
B: Bar graphs (derived from Figure 3A) showing extent of protection of staurosporine 
treated cell population following Z=VAD treatment. * indicates p value < 0.02 (using a 
paired t-test).. 
C: Cytograms obtained for MCF-7 and MCF-7TaxR cells following 48h continuous 
exposure to csiplatin 20μM in the absence and presence of Z-VAD and for paclitaxel 
20nM. Data shown are representative of repeat experiments and the numbers refer to the 
mean (and standard deviation) live (PI and FITC negative) populations (expressed as a 
percentage of the untreated controls)  taken from >3 repeat experiments. P values 
obtained for MCF-7 -/+ Z-VAD with cisplatin = 0.003 and the same figure obtained for 
MCF-7TaxR was >0.5; p values obtained for MCF-7 -/+ Z-VAD with paclitaxel = 
0.003 and the same figure obtained for MCF-7TaxR was 0.5 (using a paired t-test). 
 
FIGURE 4: A: Assessment of autophagic response of breast cancer cell lines to the 
effects of bafilomycin inhibition following treatment with 0.5 µM staurosporine. Bar 
graphs represent the mean (-/+ SD) for > 3 repeat experiments of the red fluorescence 
measured in the lower quadrant of the cytograms. Reduced values indicate migration to 
increased red and green fluorescence with formation of autophagic vesicles and reversal 
with bafilomycin. **  p = 0.038, *** p = 0.012 using paired students t-test. 
B: Western immunoblotting of MCF-7 parental and paclitaxel resistant cells following 
treatment with staurosporine. Whole cell lysates were made of cells following 24h and 
48h treatment and subjected to SDS-PAGE electrophoresis using NOVEX Bis-Tris gels 
(7-12% or 10%) and buffer system. Following transfer to PVDF membranes proteins 
AJABNOOR et al. 2011 
 22
were detected using the appropriate rabbit polyclonal antibody (Cell Signaling 
Technologies, obtained from New England Biolabs, Hitchin, UK) and then subjected to 
incubation with a secondary-alkaline phosphatise conjugated antibody with subsequent 
chemiluminescent detection. All membranes were stripped and reprobed for actin as the 
loading control. Data shown are representative of 3 repeat experiments. 
 
FIGURE 5: Confocal fluorescence microscopy imaging for LC-3 detection in MCF-7 
and MCF-7TaxR cell lines. Cells were incubated for 24h with 0.25μM staurosporine 
(ii), or 0.5μM staurosporine (iii) and compared with untreated controls (i). Images (i) – 
(iii) were co-stained with the nuclear dye TOPRO-3 and images (iv) were stained for 
LC-3 alone (Alexa-Fluor 488 associated fluorescence). Images D (1) and (2) are 
enlarged images from B(iv) and C(iv) showing deposition of LC3II granules in vacuoles 
in MCF-7 parental and MCF-7TaxR paclitaxel resistant lines, respectively. 
 
FIGURE 6: A: Reduction in cisplatin sensitivity of breast cancer cells following co-
treatment with autophagy inhibitors. Data shown are IC50 values obtained using the 
MTT assay and represent the means and SD for > 3 repeat experiments. P values were 
calculated using the paired student’s t-test for IC50 cisplatin alone versus the IC50 for 
combination of cisplatin with 3-methyladenine (3-MA) or LY294002. * = p <0.05, ** = 
p <0.02. 
B: IC50 values obtained for MCF-7 cell lines treated with the mTOR inhibitor 
rapamaycin. * Denotes a p value of <0.02 (using a paired student’s t-test). 
C: Western immunoblotting of whole cell lysate preparations of MCF-7 and paclitaxel 
resistant sublines treated with RAD001 (100nM) for 48h. Whole cell lysates of control 
and drug treated cultures were subjected to SDS-PAGE electrophoresis 10% Bis-Tris 
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gels (NOVEX) , western transfer onto PVDF membranes and probing with primary 
antibodies to LC-3I/II (Cell Signaling Technology), survivin (Santa Cruz). Membranes 
were then subjected to incubation with a secondary-alkaline phosphatase conjugated 
antibody with subsequent chemiluminescent detection. All membranes were stripped 
and reprobed with an antibody to GAPDH (Sigma Aldrich), n= 3. 
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